Skip to main content
AB

Abivax

Paris, France
Last funding
$45.0M
Post-IPO EquityMay 2026

Abivax develops medicines that alter the body's natural immune system mechanisms.

About Abivax

How much funding has Abivax raised?

Abivax has raised $45.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.

Who are Abivax's investors?

Abivax's investors include TCG Crossover, Samsara BioCapital, Sofinnova Partners, Great Point Partners, Deerfield.

Where is Abivax headquartered?

Abivax is headquartered in Paris, France.

What does Abivax do?

Abivax develops medicines that alter the body's natural immune system mechanisms.

What stage is Abivax at?

Abivax is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Abivax — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/abivax. Accessed November 15, 2026.
APA
VCBacked. (2026). Abivax — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/abivax
Wikipedia (cite web)
{{cite web |title=Abivax — Funding & Investors |url=https://www.vcbacked.co/company/abivax |website=VCBacked |access-date=November 15, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Abivax? Request a listing update

Founder contacts
m***@abivax.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →